Evaluation of the post-vaccination immune response to HPV in the general population with and without a history of viral infection – literature data analysis

Human papillomavirus (HPV) vaccines induce strong and long-lasting immune protection, significantly reducing HPV-related diseases. This review summarizes current evi­dence on post-vaccination immune responses in the general po­pu­la­tion, comparing individuals with and without prior HPV infection. Studies show that HPV-naive individuals achieve high seroconversion rates and antibody titers ex­ce­eding those from natural infection, with immunity las­ting over a decade. Previously infected but DNA-negative in­di­vi­duals exhibit anamnestic immune responses and com­pa­ra­ble antibody avidity, while DNA-positive cases gain mainly preventive benefits against new infections. Overall, HPV vaccination provides durable, high-quality immunity in both groups, supporting its broad implementation as a primary preventive tool against HPV-associated malig­nan­cies.